HC Wainwright restated their buy rating on shares of Cytokinetics, Incorporated (NASDAQ:CYTK) in a research note released on Wednesday morning. They currently have a $26.00 price target on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Zacks Investment Research upgraded Cytokinetics, from a hold rating to a buy rating and set a $15.00 price objective for the company in a report on Monday, August 7th. Cowen and Company restated a buy rating and issued a $19.00 price objective on shares of Cytokinetics, in a report on Friday, August 4th. BidaskClub upgraded Cytokinetics, from a hold rating to a buy rating in a report on Tuesday, July 25th. Cantor Fitzgerald restated a buy rating and issued a $21.00 price objective on shares of Cytokinetics, in a report on Monday, September 18th. Finally, Needham & Company LLC restated a buy rating and issued a $22.00 price objective on shares of Cytokinetics, in a report on Sunday, September 17th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $21.30.

Shares of Cytokinetics, (NASDAQ CYTK) opened at 14.30 on Wednesday. The firm’s market cap is $767.42 million. Cytokinetics, has a 12 month low of $8.57 and a 12 month high of $17.20. The firm has a 50 day moving average price of $13.51 and a 200-day moving average price of $13.58.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by ($0.03). The company had revenue of $3.05 million during the quarter, compared to the consensus estimate of $5.28 million. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. On average, analysts predict that Cytokinetics, will post ($2.46) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/09/23/hc-wainwright-reaffirms-buy-rating-for-cytokinetics-incorporated-cytk.html.

In related news, insider Caryn Gordon Mcdowell sold 11,348 shares of the firm’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $12.47, for a total value of $141,509.56. Following the completion of the sale, the insider now directly owns 21,570 shares in the company, valued at approximately $268,977.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $12.14, for a total transaction of $60,700.00. Following the completion of the sale, the chief executive officer now owns 88,385 shares of the company’s stock, valued at $1,072,993.90. The disclosure for this sale can be found here. Insiders sold a total of 164,809 shares of company stock valued at $2,412,572 over the last quarter. 7.20% of the stock is currently owned by company insiders.

A number of large investors have recently modified their holdings of the stock. FMR LLC lifted its stake in Cytokinetics, by 8.8% in the 1st quarter. FMR LLC now owns 5,655,916 shares of the biopharmaceutical company’s stock valued at $72,679,000 after purchasing an additional 456,502 shares during the last quarter. Vanguard Group Inc. lifted its stake in Cytokinetics, by 59.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,117,496 shares of the biopharmaceutical company’s stock valued at $37,721,000 after purchasing an additional 1,168,151 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Cytokinetics, in the 2nd quarter valued at about $32,488,000. State Street Corp lifted its stake in Cytokinetics, by 79.6% in the 2nd quarter. State Street Corp now owns 1,674,335 shares of the biopharmaceutical company’s stock valued at $20,259,000 after purchasing an additional 741,909 shares during the last quarter. Finally, Citigroup Inc. lifted its stake in Cytokinetics, by 9.9% in the 2nd quarter. Citigroup Inc. now owns 800,471 shares of the biopharmaceutical company’s stock valued at $9,686,000 after purchasing an additional 71,811 shares during the last quarter. Institutional investors and hedge funds own 71.51% of the company’s stock.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.